Table 1 Patient characteristics
From: A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
N (%) | ||
|---|---|---|
Sex | Male | 17 (71) |
Female | 7 (29) | |
Age | Median | 56 years |
Range | 34 to 75 years | |
Histology | Adenocarcinoma | 21 (88) |
Others | 3 (12) | |
Stage | III | 6 (25) |
IV | 18 (75) | |
Performance Status | 0 | 15 (63) |
1 | 8 (33) | |
2 | 1 (4) | |
Number of prior lines of chemotherapy | 1 | 1 (4) |
2 or more | 23 (96) |